Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 3/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4411302 | 0.84 | CNR2 (0.54) | CNR2TRPV1CNR1HDAC6MGLL | |
| SCHEMBL4407064 | 0.83 | CNR2 (0.52) | CNR2TRPV1CNR1HDAC6MGLL | |
| SCHEMBL4410788 | 0.82 | CNR2 (0.51) | CNR2TRPV1CNR1HDAC6 | |
| SCHEMBL4407827 | 0.81 | CNR2 (0.56) | CNR2TRPV1CNR1HDAC6MGLL | |
| SCHEMBL4404110 | 0.80 | TRPV1 (0.59) | CNR2TRPV1CNR1HDAC6MGLL | |
| SCHEMBL4405605 | 0.78 | HDAC6 (0.68) | CNR2TRPV1CNR1HDAC6MGLL | |
| SCHEMBL28186377 | 0.77 | CNR2 (0.59) | CNR2TRPV1CNR1HDAC6MGLL | |
| SCHEMBL22205171 | 0.76 | TRPV1 (0.46) | CNR2TRPV1CNR1HDAC6MGLL | |
| SCHEMBL4407129 | 0.73 | TRPV1 (0.86) | CNR2TRPV1CNR1HDAC6MGLL | |
| SCHEMBL4407046 | 0.73 | TRPV1 (0.55) | CNR2TRPV1CNR1HDAC6MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105982900-A | Use of purine compound in treatment or prevention of hyperuricemic or gouty diseases | 山东亨利医药科技有限责任公司 | 2016-10-05 | — | — | CN | disclosed |
| EP-2272848-B1 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8143264-B2 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GLAXOSMITHKLINE LLC | 2011-10-20 | — | — | US | disclosed |
| CN-101282977-B | Xanthine derivatives as selective hm74a agonists | SMITHKLINE BEECHAM CORP | 2011-07-27 | — | — | CN | disclosed |
| EP-2272848-A1 | Xanthine derivatives as selective HM74A agonists | Glaxosmithkline LLC (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| CN-101282976-A | Xanthine derivatives as selective HM74A agonists | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | CN | disclosed |
| CN-101282977-A | Xanthine derivatives as selective hm74a agonists | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | CN | disclosed |
| EP-1912991-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SmithKline Beecham Corporation (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1912992-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SmithKline Beecham Corporation (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017261-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017262-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, XDH, GPR88 | CNR2 236/4885TRPV1 1181/4885CNR1 121/4885 |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, GPR88, XDH | CNR2 231/4885TRPV1 1166/4885CNR1 119/4885 |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | XDH, GPR84, GPR88 | CNR2 240/4885TRPV1 1297/4885CNR1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.